- Home
- STAI vs CVM Comparison
STAI vs CVM Comparison
Compare STAI & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- CVM
- Stock Information
- Founded
- STAI 2011
- CVM 1983
- Country
- STAI United States
- CVM United States
- Employees
- STAI N/A
- CVM N/A
- Industry
- STAI
- CVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STAI
- CVM Health Care
- Exchange
- STAI Nasdaq
- CVM Nasdaq
- Market Cap
- STAI 22.6M
- CVM 18.1M
- IPO Year
- STAI N/A
- CVM 1987
- Fundamental
- Price
- STAI $0.46
- CVM $9.53
- Analyst Decision
- STAI
- CVM
- Analyst Count
- STAI 0
- CVM 0
- Target Price
- STAI N/A
- CVM N/A
- AVG Volume (30 Days)
- STAI 24.9M
- CVM 386.2K
- Earning Date
- STAI 01-01-0001
- CVM 08-14-2025
- Dividend Yield
- STAI N/A
- CVM N/A
- EPS Growth
- STAI N/A
- CVM N/A
- EPS
- STAI N/A
- CVM N/A
- Revenue
- STAI $907,637.00
- CVM N/A
- Revenue This Year
- STAI N/A
- CVM N/A
- Revenue Next Year
- STAI N/A
- CVM N/A
- P/E Ratio
- STAI N/A
- CVM N/A
- Revenue Growth
- STAI N/A
- CVM N/A
- 52 Week Low
- STAI $0.42
- CVM $1.98
- 52 Week High
- STAI $9.07
- CVM $39.30
- Technical
- Relative Strength Index (RSI)
- STAI N/A
- CVM 65.33
- Support Level
- STAI N/A
- CVM $8.04
- Resistance Level
- STAI N/A
- CVM $9.42
- Average True Range (ATR)
- STAI 0.00
- CVM 0.94
- MACD
- STAI 0.00
- CVM -0.05
- Stochastic Oscillator
- STAI 0.00
- CVM 90.37
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development of the treatment of cancer and other diseases using the immune system. The Company's core capabilities include drug discovery, research, development, and manufacturing of complex biological substances. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.